Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) - Lee, J S; Hirsh, V; Park, K (J Clin Oncol, 2012)
, et al.